Modificare „Passage Bio, Inc.”

Pagina dedicata companiei Passage Bio, Inc. listata cu simbolul US.PASG

==Descriere companie==
Passage Bio, Inc. is (https://www.passagebio.com/) a clinical-stage genetic medicines company. It is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (Î²-gal) for gangliosidosis (GM1). Its second product candidate, PBFT02, utilizes AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN) for frontotemporal dementia (FTD) caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC) for Krabbe disease. It also has four programs in the research stage: PBML04 for metachromatic leukodystrophy (MLD); PBAL05 for amyotrophic lateral sclerosis (ALS); PBCM06 for Charcot-Marie-Tooth Type 2A (CMT2A), and other.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.PASG" />

==Ultimele stiri despre Passage Bio, Inc. (US.PASG)==
<dynamicpagelist>
category=US.PASG
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.PASG]][[Categorie:Stiri despre companii]]